-
公开(公告)号:US20220220043A1
公开(公告)日:2022-07-14
申请号:US17608318
申请日:2020-04-28
申请人: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Université de Nantes , CHU Nantes , Centre National de la Recherche Scientifique
摘要: The present invention relates to a method for radioiodination or radioastatination of a biomolecule such as proteins and antibodies by reacting a biomolecule carrying a hetero(aryl) boronic acid group with a radioiodide or astatide salt, in the presence of a catalyst and a ligand, in a buffer solution, in order to obtain a radioiodo- or astatolabeled biomolecule. The method of the invention is thus a single step method easy to be implemented and efficient for both radioiodination and radioastatination of antibodies.
-
公开(公告)号:US20210401940A1
公开(公告)日:2021-12-30
申请号:US17371646
申请日:2021-07-09
IPC分类号: A61K38/20 , A61K45/06 , A61K31/436 , G01N33/564 , G01N33/68
摘要: The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
-
公开(公告)号:US11131544B2
公开(公告)日:2021-09-28
申请号:US16087290
申请日:2017-03-23
发明人: Romain Guyard , Yann Lecieux , Cyril Lupi , Dominique Leduc
IPC分类号: G01B11/255 , G01B11/16
摘要: An optical fiber curvature sensor. Two networks (R1, R2) with periodic longitudinal modulation of the refractive index of the optical fiber core are inscribed in the fiber (F) one behind the other or one on top of the other. The networks are configured to respectively reflect wavelengths λ1 and λ2 such that λ1=λB+ΔλB1 and λ2=λB+ΔλB2, where λB is the Bragg wavelength of the networks and where λB1 and λB2 are shifts sensitive to the temperature, to deformations and to the curvature of the optical fiber. The two networks are defined so that the quantities ΔλB1 and ΔλB2 have substantially identical sensitivity to temperature and to deformations and substantially opposite sensitivity to curvature.
-
公开(公告)号:US10961580B2
公开(公告)日:2021-03-30
申请号:US15537337
申请日:2015-12-18
申请人: INSERM (Institut National de la Santé et de la Recherche Médicale) , Université de Nantes , Centre Hospitalier Universitaire de Nantes
发明人: Sophie Brouard , Magali Giral , Richard Danger
IPC分类号: C12Q1/68 , C12P19/34 , C12Q1/6883 , G01N33/50
摘要: The invention relates to a method for predicting graft alterations in a transplanted patient, comprising a step of determining the expression levels of bactericidal/permeability-increasing protein (BPI), chemokine (C motif) ligand 1 (XCL1) and thioredoxin domain containing 3 (TXNDC3) genes in a biological sample obtained from said transplanted patient.
-
公开(公告)号:US20200319164A1
公开(公告)日:2020-10-08
申请号:US16303771
申请日:2017-05-24
申请人: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITÉ DE NANTES , CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
发明人: Carole GUILLONNEAU , David LAPLAUD , Séverine BEZIE , Bryan NICOL
摘要: The present invention relates to methods for detecting, assessing severity and treating multiple sclerosis. The inventors showed an impairment of the function of CD8+ Treg cells in MS patients and they demonstrated here that several criteria correlated with the disease severity i.e. the percentage of CD8+CD45RCintCD161lowValpha7− T cells in the blood, the secretion of IFNg and IL10 and the suppressive activity of the CD8+CD45RCintCD161lowValpha7− T cells. In particular, the present invention relates to a method for determining whether a subject has or is at risk of having multiple sclerosis comprising i) determining the percentage of CD8+CD45RCintCD161lowValpha7− T cells in a biological sample obtained from the subject, ii) comparing the percentage determined at step i) with a predetermined reference value and iii) detecting differential in the percentage determined at step i) with the predetermined reference value indicates that the subject has or is at risk of having multiple sclerosis.
-
公开(公告)号:US20200240771A1
公开(公告)日:2020-07-30
申请号:US16087290
申请日:2017-03-23
发明人: Romain GUYARD , Yann LECIEUX , Cyril LUPI , Dominique LEDUC
IPC分类号: G01B11/255 , G01B11/16
摘要: An optical fiber curvature sensor. Two networks (R1, R2) with periodic longitudinal modulation of the refractive index of the optical fiber core are inscribed in the fiber (F) one behind the other or one on top of the other. The networks are configured to respectively reflect wavelengths λ1 and λ2 such that λ1=λB+ΔλB1 and λ2=λB+ΔλB2, where λB is the Bragg wavelength of the networks and where λB1 and λB2 are shifts sensitive to the temperature, to deformations and to the curvature of the optical fiber. The two networks are defined so that the quantities ΔλB1 and ΔλB2 have substantially identical sensitivity to temperature and to deformations and substantially opposite sensitivity to curvature.
-
公开(公告)号:US20200231986A1
公开(公告)日:2020-07-23
申请号:US16650035
申请日:2018-09-28
申请人: Massachusetts Eye and Ear Infirmary , The Schepens Eye Research Institute, Inc. , Université de Nantes , Centre Hospitalier Universitaire de Nantes , Institut National de la Santé et de la Recherche Médicale
发明人: Eduard Ayuso , Cecile Robin , Magalie Penaud-Budloo , Achille Francois , Véronique Blouin , Luk H. Vandenberghe , Anna Claire Maurer
IPC分类号: C12N15/86 , C07K14/005
摘要: This disclosure relates to the field of high scale production of recombinant Adeno-Associated Viruses (AAVs). The inventors have conceived of specific nucleic acid constructs that allow for high scale production of recombinant AAV particles in insect cells. Importantly, these nucleic constructs do not require the production of a heterologous AAP. This disclosure thus relates to a nucleic acid for producing AAV capsids in insect cells, where the nucleic acid includes a first open reading frame encoding the VP1, VP2, and VP3 proteins, and a second open reading frame encoding the Assembly-Activating Protein (AAP).
-
8.
公开(公告)号:US20200010519A1
公开(公告)日:2020-01-09
申请号:US16492221
申请日:2018-03-09
申请人: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE(INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , MUSEUM NATIONAL D'HISTOIRE NATURELLE , UNIVERSITÉ DE NANTES
发明人: Ignacio ANEGON , Marine CHARPENTIER , Jean-Paul CONCORDET , Carine GIOVANNANGELLI , Bernard LOPEZ
摘要: The present invention relates to nuclease protein fusions for enhancing genome editing by homology-directed transgene integration (HDI). The inventors found that the rate of HDI mediated by the CRISPR/Cas9 system may be substantially improved by providing the Cas9 nuclease in the form of a fusion protein with at least the N-terminal domain of the CtIP protein. CtIP proteins are involved in the early steps of homologous recombination. In addition, the inventors identified the subdomains of the N-terminal domain of the CtIP protein that are important for improving the HDI rate. Thus, the invention relates to fusion proteins comprising a Cas9 protein, a tetramerization domain of a CtIP protein and a dimerization domain of a CtIP protein. Particularly, the inventors have tested these fusion proteins HEK293 cells, RG37DR cells and Sprague-Dawley rats.
-
9.
公开(公告)号:US20190060405A1
公开(公告)日:2019-02-28
申请号:US16174837
申请日:2018-10-30
IPC分类号: A61K38/20 , G01N33/68 , G01N33/564 , A61K45/06 , A61K31/436
摘要: The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
-
10.
公开(公告)号:US10155025B2
公开(公告)日:2018-12-18
申请号:US15326515
申请日:2015-07-17
IPC分类号: A61K38/20 , A61K45/06 , A61K31/436 , G01N33/564 , G01N33/68
摘要: The invention relates to an isolated interleukin-34 (IL-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of IL-34 in a biological sample obtained from said patient, wherein the presence of IL-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies.
-
-
-
-
-
-
-
-
-